

Intellia
CRISPR: Hereditary Angioedema (HAE)
Freelance Copywriter/Creative Director
Unbranded
Rare Diseases - New Business Pitch
Intellia was looking for a partner to bring NTEL-2021 and NTEL-2022 to market. These CRISPR-based therapies are genuinely transformative treatments that will usher in a new era for rare genetic diseases such as HAE, ATTR-CM, and ATTR-PN. Beyond rare diseases, the launch of gene editing treatments will be an inflection point in all of healthcare. But the idea of editing one’s genetic code still feels sci-fi and frightening to many. The objective was to make the significance of the CRISPR therapies clear while simultaneously letting patients see them feel like a natural step, not something from the future, but something from their lives.


